Opinion|Videos|May 27, 2025
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Author(s)Neal Shore, MD, FACS
Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency.
Advertisement
Episodes in this series
Comparison of PSA Thresholds
Key Themes:
- Comparison between ultra-low threshold (<0.02 ng/mL) and traditional thresholds (<0.1 or <0.2 ng/mL)
- Sensitivity and specificity considerations
- Prognostic value of different PSA cutoff points
Expert Insights:
- Dr Shore discussed the differences between the ultra-low PSA threshold and more conventional thresholds commonly used in clinical practice.
The conversation addressed the sensitivity, specificity, and potential prognostic significance of various PSA cutoff points.
Advertisement
Related to this article
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.
Lorelei A. Mucci, ScD, MPH, discusses the evolving evidence surrounding diet, physical activity, and other lifestyle factors in prostate cancer care.
Urologists compare ADT plus ARPI doublets and docetaxel triplets in mCSPC, weighing efficacy, safety, cognition, and cost against patient goals.
Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.
A randomized trial will test whether an app-guided, at-home PSA screening approach can improve prostate cancer screening among Black men.
Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
2
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
3
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
4
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
5